SOLIGENIX INC (SNGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.38-0.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SNGX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | 0.1 | 0.8 | 0.9 | 0.8 | 2.4 | 4.6 | 5.2 | 5.4 | 10.4 | 8.8 | 7.0 | 3.2 | 3.1 | 7.7 |
| Total Revenues | — | — | 0.1 | 0.8 | 0.9 | 0.8 | 2.4 | 4.6 | 5.2 | 5.4 | 10.4 | 8.8 | 7.0 | 3.2 | 3.1 | 7.7 |
| Cost of Revenues | — | — | 0.1 | 0.7 | 0.6 | 0.7 | 1.8 | 3.6 | 4.6 | 4.3 | 8.4 | 6.9 | 5.3 | 2.5 | 2.6 | 2.1 |
| Gross Profit | — | — | — | 0.1 | 0.4 | 0.1 | 0.5 | 1.1 | 0.6 | 1.1 | 2.0 | 1.9 | 1.7 | 0.7 | 0.6 | 5.6 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 6.6 | 7.5 | 5.2 | 3.3 | 7.9 | 8.2 | 9.8 | 8.1 | 6.8 | 5.5 | 4.3 | 5.4 | 5.1 | 5.1 | 2.6 | 6.3 |
| Operating Income | (11.0) | (11.8) | (9.4) | (7.7) | (14.2) | (13.1) | (18.6) | (10.5) | (9.1) | (7.6) | (5.7) | (7.1) | (10.8) | (7.2) | (4.7) | (3.0) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest & Investment Income | — | — | — | — | — | — | — | 0.1 | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Other Non-Operating Income / Expenses | 0.3 | 0.3 | 0.8 | (0.2) | (0.7) | (0.3) | 0.1 | 0.6 | — | 0.0 | 1.9 | (1.2) | 3.4 | (3.7) | 0.0 | 0.0 |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 |
| EBT, Incl. Unusual Items | (10.7) | (11.6) | (8.7) | (7.9) | (15.0) | (13.4) | (18.5) | (10.0) | (8.9) | (7.6) | (3.8) | (8.3) | (7.3) | (10.8) | (4.7) | (3.0) |
| Income Tax Expense | — | (0.5) | (0.4) | (1.8) | (1.2) | (0.9) | (0.8) | (0.6) | (0.4) | (0.4) | (0.5) | (0.5) | (0.6) | (0.8) | (0.5) | (0.6) |
| Net Income | ||||||||||||||||
| Net Income | (10.3) | (11.1) | (8.3) | (6.1) | (13.8) | (12.6) | (17.7) | (9.4) | (8.9) | (7.1) | (3.2) | (7.8) | (6.7) | (10.1) | (4.2) | (2.4) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.64) | (2.14) | (4.98) | (12.66) | (4.81) | (4.69) | (0.64) | — | — | (1.16) | (0.93) | (3.00) | (0.32) | — | — | — |
| Diluted EPS | (0.64) | (2.14) | (4.98) | (12.66) | (4.81) | (4.69) | (0.64) | — | — | (1.16) | (1.34) | (3.00) | (0.43) | — | — | — |
| Basic Weighted Avg Shares | 16.0 | 5.2 | 1.7 | 0.5 | 2.9 | 2.7 | 27.5 | — | — | 6.1 | 3.5 | 2.6 | 20.6 | — | — | — |
| Diluted Weighted Avg Shares | 16.0 | 5.2 | 1.7 | 0.5 | 2.9 | 2.7 | 27.5 | — | — | 6.1 | 3.6 | 2.6 | 23.6 | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | (13.1) | (18.5) | (10.5) | (9.0) | (7.5) | (5.6) | (6.9) | (10.5) | (6.9) | (4.5) | (2.7) |
| EBIT | (11.0) | (11.8) | (9.4) | (7.7) | (14.2) | (13.1) | (18.6) | (10.5) | (9.1) | (7.6) | (5.7) | (7.1) | (10.8) | (7.2) | (4.7) | (3.0) |
| Effective Tax Rate | — | — | — | 22.4% | 7.7% | 6.4% | 4.5% | 6.1% | 4.7% | 5.5% | 14.0% | 5.9% | 8.4% | 6.9% | 11.1% | 19.4% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.